PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(02): 176-182
DOI: 10.1055/s-0044-1779721
Brief Communication

Pharmacoeconomic Analysis of Treating Lung Cancer with Different Regimens Using the Cheapest and Costliest Brand and the Generic Jan Aushadhi Drugs Marketed in India

Abhishek Krishna
1   Department of Radiation Oncology, Mysore Medical College and Research Institute, Mysuru, Karnataka, India
,
Princy Louis Palatty 
2   Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, Kerala, India
,
Thomas George
3   Department of Internal Medicine, Coney Island Hospital, Brooklyn, New York, United States
,
Manjeshwar Shrinath Baliga 
4   Research Unit, Mangalore Institute of Oncology, Pumpwell, Mangaluru, Karnataka, India
› Institutsangaben Source of Funding None declared.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background/Purpose of the Study The costs of chemotherapy drugs which are vital in the treatment of lung cancer can be exorbitant. The current study was undertaken to ascertain cost minimization analysis by comparing costliest and cheapest branded with Jan Aushadhi (JA) drugs marketed in India.

Methods The cost of costliest, cheapest branded, and JA drugs were collected from the designated reference sites. The cost difference, cost ratio, and percentage of cost variation were calculated as per cost minimization study guidelines.

Results The results of the analysis suggest that the JA drugs were much cheaper than the branded drugs and when used in regimens resulted in substantial cost savings. The biggest financial advantage was seen in the commonly used cisplatin–pemetrexed regimen where cost saving of Rs. 268,002 was observed for the whole treatment of six cycles. Using JA drugs also reduced the cost for the targeted therapy with gefitinib and erlotinib.

Conclusion The cost minimization study, which is the first in this field of lung cancer, clearly indicates the usefulness of JA drugs in reducing financial costs for the patient.

Keywords

lung cancer - anticancer drugs - pharmacoeconomics - Jan Aushadhi - cost difference - cost ratio - percentage of cost variation

Ethics

No patient-specific data or information were required for the study focus on the pharmacoeconomics of drug pricing. Cost of data on medications is available in public domain, and the study did not require approval from an Institutional Review Board.


Ethics Committee Approval

Not required.




Publikationsverlauf

Artikel online veröffentlicht:
21. März 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer 2016; 5 (03) 95-103
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Kolasani BP, Malathi DC, Ponnaluri RR. Variation of cost among anti-cancer drugs available in Indian market. J Clin Diagn Res 2016; 10 (11) FC17-FC20
    PubMedGoogle Scholar
  • 3 Kashyap A, Balaji MN, Chhabra M, Rashid M, Muragundi PM. Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India. Expert Rev Pharmacoecon Outcomes Res 2020; 20 (04) 355-361
    CrossrefPubMedGoogle Scholar
  • 4 National Institute of Nutrition. India n.d. Accessed September 30, 2022, at: https://www.nin.res.in/RDA_short_Report_2020.html
    Google Scholar
  • 5 Chandran S, Rao S, Prasad KR. et al. Alterations in hematological, liver and renal parameter levels in people afflicted with lung cancer. Int J Medical Laboratory Research. 2019; 4 (01) 30-34
    CrossrefGoogle Scholar
  • 6 Singh N, Agrawal S, Jiwnani S, Khosla D, Malik PS, Mohan A. et al. Editorial: Lung Cancer Worldwide. Lung Cancer in India. J Thorac Oncol 2021; 16 (08) 1250-1266
    CrossrefPubMedGoogle Scholar
  • 7 George T, Baliga MS. Generic anticancer drugs of the Jan Aushadhi scheme in India and their branded counterparts: the first cost comparison study. Cureus 2021; 13 (11) e19231
    PubMedGoogle Scholar
  • 8 Scagliotti GV, Parikh P, von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21) 3543-3551
    CrossrefPubMedGoogle Scholar
  • 9 Lynch TJ, Bell DW, Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21) 2129-2139
    CrossrefPubMedGoogle Scholar
  • 10 Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer 2022; 170: 41-51
    CrossrefPubMedGoogle Scholar